CD19 and precursor B-cell acute lymphoblastic leukemia: Blinatumomab, a CD3/CD19 BiTE, is the first approved regiment for clinical use in this category after the impressive results demonstrated in patients with relapsed/refractory B acute lymphoblastic leukemia (B-ALL) [48,49].